公开(公告)号：US6060263A

公开(公告)日：2000-05-09

申请号：US400742

申请日：1999-09-21

申请人： David W. Leung ,  James W. West ,  Christopher K. Tompkins

发明人： David W. Leung ,  James W. West ,  Christopher K. Tompkins

IPC分类号： C12N9/10 ,  C12N15/54 ,  C12Q1/48

CPC分类号： C12N9/1029

摘要： There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

公开(公告)号：US08513390B2

公开(公告)日：2013-08-20

申请号：US13455924

申请日：2012-04-25

申请人： Nancy E. Stagliano ,  James W. West ,  Kathryn Kamath ,  Paul H. Bessette ,  Fred Gluck ,  Jason Sagert ,  Patrick Daugherty

发明人： Nancy E. Stagliano ,  James W. West ,  Kathryn Kamath ,  Paul H. Bessette ,  Fred Gluck ,  Jason Sagert ,  Patrick Daugherty

IPC分类号： C07K16/28 ,  C07K14/00 ,  C07K16/46 ,  A61K39/00 ,  A61K38/10 ,  A61K38/08

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K47/6845 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/507 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001 ,  C07K16/00 ,  C07K16/18 ,  C07K16/241 ,  C07K16/28 ,  C07K16/2818 ,  C07K16/2845 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/50 ,  G01N33/6845 ,  G01N33/6854

摘要： The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.

公开(公告)号：US20120244154A1

公开(公告)日：2012-09-27

申请号：US13411409

申请日：2012-03-02

申请人： Patrick Daugherty ,  Nancy Stagliano ,  Jerry Thomas ,  Kathryn Kamath ,  James W. West ,  Sanjay Khare

发明人： Patrick Daugherty ,  Nancy Stagliano ,  Jerry Thomas ,  Kathryn Kamath ,  James W. West ,  Sanjay Khare

IPC分类号： C07K19/00 ,  C12P21/02 ,  C12N15/63 ,  A61K39/395 ,  C12N15/62

CPC分类号： C07K16/22 ,  C07K16/24 ,  C07K16/2818 ,  C07K16/2836 ,  C07K16/42 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/50 ,  C12N15/1034 ,  C12N15/1044

摘要： Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.

公开(公告)号：US20120207756A1

公开(公告)日：2012-08-16

申请号：US13455924

申请日：2012-04-25

申请人： Nancy E. Stagliano ,  James W. West ,  Kathryn Kamath ,  Paul H. Bessette ,  Frederick W. Gluck ,  Jason Sagert ,  Patrick Daugherty

发明人： Nancy E. Stagliano ,  James W. West ,  Kathryn Kamath ,  Paul H. Bessette ,  Frederick W. Gluck ,  Jason Sagert ,  Patrick Daugherty

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61P9/00 ,  C07K1/107 ,  C12N15/63 ,  C12P21/00 ,  C12P21/02 ,  C12N15/62 ,  C07K19/00

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K47/6845 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/507 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001 ,  C07K16/00 ,  C07K16/18 ,  C07K16/241 ,  C07K16/28 ,  C07K16/2818 ,  C07K16/2845 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/50 ,  G01N33/6845 ,  G01N33/6854

摘要： The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.

摘要翻译： 本公开提供了修饰的抗体，其含有用掩蔽部分（MM）修饰的抗体或抗体片段（AB）。 这样的修饰抗体可以进一步与可切割部分（CM）偶联，产生可激活抗体（AAs），其中CM能够被切割，还原，光解或以其它方式修饰。 AAs可以表现出可激活的构象，使得AB在例如通过在能够切割，还原或光解所述蛋白质的试剂存在下，通过CM的切割，还原或光解来除去MM来更容易地进行靶标 厘米。 本公开进一步提供了制备和使用这些修饰抗体和可激活抗体的方法。

公开(公告)号：US20110059087A1

公开(公告)日：2011-03-10

申请号：US12870199

申请日：2010-08-27

申请人： Katherine E. Lewis ,  Scott R. Presnell ,  James W. West ,  Robert Mabry ,  Brent Meengs ,  Steven D. Levin

发明人： Katherine E. Lewis ,  Scott R. Presnell ,  James W. West ,  Robert Mabry ,  Brent Meengs ,  Steven D. Levin

IPC分类号： A61K39/395 ,  C07K16/24 ,  C12N5/0783 ,  A61P25/28 ,  A61P1/00

CPC分类号： C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

摘要翻译： 本发明涉及通过其p19亚基或IL-17和IL-23（通过p19）阻断，抑制，降低，拮抗或中和IL-17，IL-23的活性。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。

公开(公告)号：US20100074905A1

公开(公告)日：2010-03-25

申请号：US12560637

申请日：2009-09-16

申请人： Cindy A. Sprecher ,  Julie E. Novak ,  James W. West ,  Scott R. Presnet ,  Richard D. Holly ,  Andrew J. Nelson

发明人： Cindy A. Sprecher ,  Julie E. Novak ,  James W. West ,  Scott R. Presnet ,  Richard D. Holly ,  Andrew J. Nelson

IPC分类号： A61K39/395 ,  A61K38/16 ,  A61P37/06

CPC分类号： C07K16/2866 ,  A61K38/00 ,  C07K14/7155 ,  C07K2317/73 ,  C07K2319/00

摘要： Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

摘要翻译： 公开了可用作新型细胞因子拮抗剂的可溶性zalpha11受体的新型多肽组合，编码多肽的多核苷酸以及相关组合物和方法，以及用于检测刺激造血，淋巴和骨髓细胞增殖和/或发育的配体的方法 体外和体内。 配体结合受体多肽也可用于在体外和体内阻断zalpha11配体活性，并可与zalpha11配体和其他细胞因子结合使用以选择性刺激免疫系统。 本发明还包括生产蛋白质的方法，用途及其抗体。

公开(公告)号：US20090304719A1

公开(公告)日：2009-12-10

申请号：US12196269

申请日：2008-08-21

申请人： Patrick Daugherty ,  Nancy Stagliano ,  Jerry Thomas ,  Kathryn Kamath ,  James W. West ,  Sanjay Khare

发明人： Patrick Daugherty ,  Nancy Stagliano ,  Jerry Thomas ,  Kathryn Kamath ,  James W. West ,  Sanjay Khare

IPC分类号： A61K39/395 ,  C07K2/00 ,  C07K14/00 ,  C40B30/04 ,  C40B40/10 ,  C40B40/02 ,  C12N15/11 ,  C40B50/06 ,  A61K38/16 ,  C12P21/06 ,  G01N33/53 ,  C07K16/00 ,  A61K49/00 ,  C12N9/68 ,  C12N9/50

CPC分类号： C07K16/22 ,  C07K16/24 ,  C07K16/2818 ,  C07K16/2836 ,  C07K16/42 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/50 ,  C12N15/1034 ,  C12N15/1044

摘要： The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.

摘要翻译： 本公开提供了可激活的结合多肽（ABP），其包含靶结合部分（TBM），掩蔽部分（MM）和可切割部分（CM）。 本公开提供可激活的抗体组合物，其含有含有抗原结合结构域（ABD），MM和CM的TBM。 此外，本公开还提供了包含第一TBM，第二TBM和CM的ABP。 ABP表现出“可激活”构象，使得当不能切割CM时，在存在能够切割CM的切割剂的情况下，TBM中的至少一种在未切割时难以接触。 本公开进一步提供候选ABP的文库，筛选鉴定这种ABP的方法和使用方法。 本公开进一步提供了具有结合VEGF，CTLA-4或VCAM，具有结合VEGF的第一TBM的ABP和结合FGF的第二TBM的TBM以及组合物和使用方法的ABP。

公开(公告)号：US07223564B2

公开(公告)日：2007-05-29

申请号：US10315379

申请日：2002-12-09

申请人： Christopher S. Piddington ,  James W. West ,  Richard D. Holly ,  Steven K. Burkhead

发明人： Christopher S. Piddington ,  James W. West ,  Richard D. Holly ,  Steven K. Burkhead

IPC分类号： C12N15/16 ,  C12N15/63 ,  C12N5/00 ,  C07K14/475 ,  C07K4/12

CPC分类号： C07K14/47 ,  C07K14/475

摘要： This present invention is directed to polypeptide and polynucleotide molecules that encode a four-helical bundle cytokine. The cytokine has been designated zsig81, and has restricted expression in primarily heart, lung and liver. zsig81 has been shown to stimulate proliferation of hematopoietic cells and will be useful expansion of these cells, as well as conditions associated with hematopoietic cells. The invention is directed to antibodies and methods of making zsig81 polypeptides, as well.

摘要翻译： 本发明涉及编码四螺旋束细胞因子的多肽和多核苷酸分子。 细胞因子被指定为zsig81，并且主要限制在心脏，肺和肝中的表达。 已经显示zsig81刺激造血细胞的增殖，并且这些细胞的有用扩张以及与造血细胞相关的病症。 本发明还涉及制备zsig81多肽的抗体和方法。

公开(公告)号：US06432673B1

公开(公告)日：2002-08-13

申请号：US09457066

申请日：1999-12-07

申请人： Zeren Gao ,  Charles E. Hart ,  Christopher S. Piddington ,  Paul O. Sheppard ,  Kimberly E. Shoemaker ,  Debra G. Gilbertson ,  James W. West

发明人： Zeren Gao ,  Charles E. Hart ,  Christopher S. Piddington ,  Paul O. Sheppard ,  Kimberly E. Shoemaker ,  Debra G. Gilbertson ,  James W. West

IPC分类号： C12N1500

CPC分类号： C07K14/52 ,  A01K2217/05 ,  A61K38/1858 ,  C07K14/475 ,  C12N2799/022

摘要： Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.

摘要翻译： 公开了多肽生长因子，其制备方法，编码它们的多核苷酸，针对它们的抗体及其使用方法。 多肽包含与SEQ ID NO：2的残基46-163或SEQ ID NO：2的残基235-345至少90％相同的氨基酸区段。 还公开了多肽的多聚体。 多肽，多聚体蛋白和多核苷酸可用于细胞和组织发育的研究和调节，作为细胞培养基的组分和诊断剂。